| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SIGLEC10 |
| Uniprot No | Q96LC7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 17-550aa |
| 氨基酸序列 | MDGRFWIRVQ ESVMVPEGLC ISVPCSFSYP RQDWTGSTPA YGYWFKAVT ETTKGAPVAT NHQSREVEMS TRGRFQLTGD PAKGNCSLVI RDAQMQDESQ YFFRVERGS YVRYNFMNDG FFLKVTALTQ KPDVYIPETL EPGQPVTVIC VFNWAFEECP PPSFSWTGA ALSSQGTKPT TSHFSVLSFT PRPQDHNTDL TCHVDFSRKG VSAQRTVRLR VAYAPRDLV ISISRDNTPA LEPQPQGNVP YLEAQKGQFL RLLCAADSQP PATLSWVLQN RVLSSSHPW GPRPLGLELP GVKAGDSGRY TCRAENRLGS QQRALDLSVQ YPPENLRVMV SQANRTVLE NLGNGTSLPV LEGQSLCLVC VTHSSPPARL SWTQRGQVLS PSQPSDPGVL ELPRVQVEHE GEFTCHARH PLGSQHVSLS LSVHYSPKLL GPSCSWEAEG LHCSCSSQAS PAPSLRWWLG EELLEGNSS QDSFEVTPSS AGPWANSSLS LHGGLSSGLR LRCEAWNVHG AQSGSILQLP DKKGLISTA FSN |
| 预测分子量 | 60 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SIGLEC10重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *"Siglec-10 interacts with SHP-1 to suppress TCR-mediated activation in human T cells"*
**作者**: Chen et al.
**摘要**: 该研究解析了重组SIGLEC10胞外段蛋白的结构，发现其通过ITIM结构域招募磷酸酶SHP-1.抑制T细胞受体(TCR)信号通路，揭示了SIGLEC10在调节T细胞免疫耐受中的作用。
2. **文献名称**: *"SIGLEC10 binds to CD24 on apoptotic cells to inhibit macrophage phagocytosis and dampen anti-tumor immunity"*
**作者**: Barkal et al.
**摘要**: 研究利用重组SIGLEC10蛋白验证其与CD24的相互作用，证明该结合通过阻断“吃我”信号抑制巨噬细胞对凋亡细胞的吞噬，并发现靶向SIGLEC10-CD24通路可增强肿瘤免疫治疗效果。
3. **文献名称**: *"Structural basis of Siglec-10 ligand recognition and its role in immune regulation"*
**作者**: Wang et al.
**摘要**: 通过X射线晶体学解析重组SIGLEC10蛋白与唾液酸配体的复合物结构，阐明其特异性结合的分子机制，并提出其在自身免疫疾病中通过抑制过度炎症反应的潜在应用。
---
以上文献均聚焦于SIGLEC10重组蛋白的结构功能研究及其在免疫调控中的生物学意义，涉及肿瘤免疫、自身免疫疾病等方向。如需具体期刊或年份信息，可进一步补充检索条件。
SIGLEC10 (sialic acid-binding immunoglobulin-type lectin 10) is a transmembrane protein belonging to the SIGLEC family of immunomodulatory receptors. It is primarily expressed on immune cells, including macrophages, dendritic cells, B cells, and subsets of T cells. Structurally, it features an N-terminal V-set immunoglobulin (Ig) domain that mediates binding to sialylated glycoconjugates, followed by multiple C2-type Ig domains, a transmembrane region, and a cytoplasmic tail containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). These motifs enable SIGLEC10 to transmit inhibitory signals, modulating immune responses by counteracting activating receptor signals.
Functionally, SIGLEC10 interacts with sialic acid-containing ligands such as CD24. PSGL-1. and gangliosides, playing roles in immune tolerance, inflammation regulation, and cell-cell communication. Its engagement typically suppresses pro-inflammatory pathways (e.g., TLR and NLRP3 inflammasome signaling) and promotes phagocytic clearance of apoptotic cells. Dysregulation of SIGLEC10 has been implicated in diseases like cancer, autoimmune disorders, and neurodegenerative conditions. For instance, the SIGLEC10-CD24 axis is studied as a "don't eat me" signal in tumor immune evasion, while reduced SIGLEC10 activity correlates with exacerbated inflammation in rheumatoid arthritis.
Recombinant SIGLEC10 proteins, often produced in mammalian expression systems to preserve glycosylation patterns, are used to study ligand interactions, signaling mechanisms, and therapeutic targeting. They serve as tools to develop blocking antibodies or fusion proteins for modulating immune responses. Recent research explores its potential as a biomarker or checkpoint target in immunotherapy, balancing immune activation and tolerance. Its dual role in homeostasis and disease underscores its importance in both basic immunology and translational medicine.
×
